Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Chen, W-C. [1 ]
Chang, P. M-H. [2 ]
Lee, Y-T. [3 ]
Lu, W-B. [4 ]
Yang, M-H. [2 ]
机构：
[1] Taipei Vet Gen Hosp, Med, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan
[4] Changzhou Wujin Peoples Hosp, Dept Med Oncol, Changzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
385P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, H-F.
    Hong, R-L.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 379 - 379
  • [2] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
    Chen, Wen-Chun
    Chu, Pen-Yuan
    Lee, Yu-Ting
    Lu, Wen-Bin
    Liu, Chun-Yu
    Chang, Peter Mu-Hsin
    Yang, Muh-Hwa
    [J]. MEDICINE, 2017, 96 (52)
  • [4] DOXORUBICIN AND CISPLATIN FOR RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    SANDLER, S
    BONOMI, P
    TAYLOR, B
    SHOWEL, J
    SLAYTON, R
    LERNER, H
    [J]. CANCER TREATMENT REPORTS, 1984, 68 (09): : 1163 - 1165
  • [5] Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma
    Adamo, V
    Ferraro, G
    Pergolizzi, S
    Sergi, C
    Laudani, A
    Settineri, N
    Alafaci, E
    Scimone, A
    Spano, F
    Spitaleri, G
    [J]. ORAL ONCOLOGY, 2004, 40 (05) : 525 - 531
  • [6] VINBLASTINE, BLEOMYCIN AND CISPLATIN FOR RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    PERRY, DJ
    WELTZ, MD
    BROWN, AW
    HENDERSON, RL
    NEGLIA, WJ
    BERENBERG, JL
    [J]. CANCER, 1982, 50 (11) : 2257 - 2260
  • [7] Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
    Okada, Takuro
    Fushimi, Chihiro
    Matsuki, Takashi
    Tokashiki, Kunihiko
    Takahashi, Hideaki
    Okamoto, Isaku
    Sato, Hiroki
    Kondo, Takahito
    Hanyu, Kenji
    Kishida, Takuma
    Ito, Tatsuya
    Yamashita, Gai
    Masubuchi, Tatsuo
    Tada, Yuichiro
    Miura, Koki
    Omura, Go
    Yamashita, Taku
    Oridate, Nobuhiko
    Tsukahara, Kiyoaki
    [J]. ANTICANCER RESEARCH, 2023, 43 (06) : 2717 - 2724
  • [8] Role of Hematological Markers in Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab
    Hagiwara, Kohei
    Matsuki, Takashi
    Okada, Takuro
    Fushimi, Chihiro
    Kondo, Takahito
    Takahashi, Hideaki
    Okamoto, Isaku
    Tokashiki, Kunihiko
    Hanyu, Kenji
    Kishida, Takuma
    Ito, Tatsuya
    Yamashita, Gai
    Tsukahara, Kiyoaki
    Masubuchi, Tatsuo
    Tada, Yuichiro
    Momiyama, Kaho
    Yaguchi, Ryohei
    Oridate, Nobuhiko
    Omura, Go
    Yamashita, Taku
    [J]. ANTICANCER RESEARCH, 2024, 44 (09) : 4057 - 4072
  • [9] Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial
    Saba, Nabil F.
    Steuer, Conor E.
    Ekpenyong, Asari
    McCook-Veal, Ashley
    Magliocca, Kelly
    Patel, Mihir
    Schmitt, Nicole C.
    Stokes, William
    Bates, James E.
    Rudra, Soumon
    Remick, Jill
    McDonald, Mark
    Abousaud, Marin
    Tan, Aik Choon
    Fadlullah, Muhammad Zaki Hidayatullah
    Chaudhary, Ritu
    Muzaffar, Jameel
    Kirtane, Kedar
    Liu, Yuan
    Chen, Georgia Z.
    Shin, Dong M.
    Teng, Yong
    Chung, Christine H.
    [J]. NATURE MEDICINE, 2023, 29 (04) : 880 - 887
  • [10] Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Shin, DM
    Glisson, BS
    Khuri, FR
    Hong, WK
    Lippman, SM
    [J]. SEMINARS IN ONCOLOGY, 1998, 25 (02) : 40 - 44
12345